Apolipoprotein (apo) B, the main protein in LDL, exists in 2 isoforms in plasma: apoB-100, which is produced in the liver, and apoB-48, which is a naturally occurring truncation of apoB-100 and is secreted in the intestine in response to dietary fat. Heterozygous subjects for hypobetalipoproteinemia (HBLP), an autosomal codominant disorder, have LDL cholesterol (C) levels between 0.52 and 1.29 mmol/L (20 to 50 mg/dL) and are asymptomatic. 1 In contrast, homozygous and compound heterozygous subjects have levels of LDL-C that range from undetectable to Ͻ0.26 mmol/L (10 mg/dL) and have variable clinical symptoms including retinitis pigmentosa, fat malabsorption, acanthocytosis, ataxia, and debilitating neurological diseases. 1 The reasons for the variability in clinical symptoms have been unclear. Welty et al 2 previously reported an asymptomatic, 54-year-old subject heterozygous for an apoB-44.4 truncation who had an undetectable plasma level of LDL-C and a very low level of apoB-100, findings suggesting that he was a compound heterozygote with a second apoB gene mutation. To locate this mutation, we amplified the entire apoB gene by using polymerase chain reaction (PCR) primers and reaction conditions as previously described. 3 The PCR products were purified and sequenced by using PCR priming oligonucleotides. Sequencing revealed a G-to-C transition at the first nucleotide of the donor splice site of intron 1 (210ϩ1G_C) in the proband and a son (Figure) .
We hypothesized that subjects with very short apoB truncations would have the full spectrum of symptoms. This hypothesis is supported by 2 siblings who are compound heterozygotes for apoB-2 and apoB-9, have no detectable LDL-C in plasma, and presented with retinitis pigmentosa, neurological deficits, and steatorrhea at 4 months and 10 years of age. 3 We further hypothesized that subjects with intermediate-length truncations (apoB-25 to 39) would have less severe symptoms; this is supported by 4 subjects. A subject homozygous for apoB-25 had no detectable LDL-C and presented with fatty diarrhea during the first year of life. 8 A 21 year-old subject homozygous for apoB-27.6 had no detectable LDL-C in plasma and presented with chronic fatty diarrhea and acanthocytosis but no retinitis pigmentosa or neurological disease. 9 A 21-year-old woman who is a compound heterozygote for apoB-39 (LDL-C not measured) and a second mutation causing a low level of apoB-100 had fat malabsorption but no retinitis pigmentosa or neurological disease. 10 Finally, a 57-year-old subject who had a 20-year history of diabetes and was homozygous for apoB-38.7 had no detectable LDL-C and no symptoms of diarrhea or malabsorption but did have retinitis pigmentosa, acanthocytosis, and loss of deep tendon reflexes despite normal vitamin E levels. 11 An exception to our hypothesis was an 8-year-old girl who was homozygous for a truncated apoB-49.6, had no detectable LDL-C, and manifested severe neurological abnormalities resulting from a nearly-complete absence of vitamin E in the plasma despite adequate intestinal fat absorption. 12 Because the homozygous apoB-38.7 and apoB-45 subjects had normal vitamin E levels, the lack of vitamin E in the apoB-49.6 subject probably did not result from the apoB mutation. 12 In summary, the amino terminal 45% of apoB appears adequate for normal function and development. Future studies correlating the clinical sequelae of HBLP with the length of apoB mutations should provide further insight into structural/functional domains of apoB. DNA sequence of splicing mutation in intron 1. Of 10 clones, 6 contained the normal apoB sequence (left), and 4 contained a G-to-C transition at the first nucleotide of the invariant dinucleotide pair, GT, in the donor splice site in intron 1 (210ϩ1G_C) (right). The mutation is indicated by an arrow in the mutant allele.
